You're asking about **1-(1-phenylcyclohexyl)-4-hydroxypiperidine**, which is also known as **(1S,4R)-1-(1-phenylcyclohexyl)-4-hydroxypiperidine**. This compound is a **chiral piperidine derivative** that has gained significant interest in research for several reasons:
**1. Potential Therapeutic Applications:**
* **Antidepressant Activity:** This compound is known to exhibit antidepressant-like effects in animal models. It is believed to act as a **selective serotonin reuptake inhibitor (SSRI)**, meaning it increases the levels of serotonin in the brain by blocking its reabsorption, which is a key mechanism of action for many antidepressants.
* **Analgesic Potential:** Some studies suggest that this compound may possess analgesic (pain-relieving) properties. This could be relevant for developing new treatments for chronic pain conditions.
**2. Chemical Synthesis and Research:**
* **Stereochemistry and Chirality:** The compound's chiral nature, with two distinct stereoisomers (enantiomers), makes it an interesting subject for synthetic chemistry research. Understanding the synthesis and properties of these enantiomers is crucial for developing potentially useful drugs.
* **Structure-Activity Relationships:** The unique structure of this compound, with its cyclohexyl and piperidine rings, allows researchers to explore the relationship between its molecular structure and its biological activity.
**3. Neuroscience Research:**
* **Serotonin Receptor Modulation:** The compound's interaction with serotonin receptors, particularly the serotonin transporter (SERT), makes it relevant for neuroscience research. Studying its effects on these receptors can provide insights into the mechanisms of serotonin signaling in the brain.
* **Behavioral Studies:** This compound is often used in animal models to study the role of serotonin in various behaviors, including anxiety, depression, and pain perception.
**Overall, 1-(1-phenylcyclohexyl)-4-hydroxypiperidine is a promising compound with potential for developing novel therapeutic agents. Its unique structure and pharmacological activity continue to drive ongoing research in the areas of medicinal chemistry, neuroscience, and pharmacology.**
**It's important to note that this compound is still in the early stages of research and its clinical applications remain to be fully established.**
1-(1-phenylcyclohexyl)-4-hydroxypiperidine: metabolite of phencyclidine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 98840 |
| CHEMBL ID | 422629 |
| SCHEMBL ID | 1262334 |
| MeSH ID | M0097980 |
| Synonym |
|---|
| 60232-85-1 |
| nsc-170516 |
| nsc170516 |
| 4-piperidinol, 1[(1-phenyl)-1-cyclohexyl]- |
| piperidine, 1-(1-phenylcyclohexyl)-4-hydroxy- |
| 1-(1-phenylcyclohexyl)-4-hydroxypiperidine |
| 4-piperidinol, 1-(1-phenylcyclohexyl)- |
| CHEMBL422629 |
| 1-(1-phenylcyclohexyl)piperidin-4-ol |
| FT-0669939 |
| 1-(1-phenyl-cyclohexyl)-piperidin-4-ol |
| ae1041687f , |
| unii-ae1041687f |
| nsc 170516 |
| n-(1-phenylcyclohexyl)-4-hydroxypiperidine |
| 4-hydroxyphencyclidine |
| 4-hydroxy phencyclidine |
| 1-(1-phenylcyclohexyl)-4-piperidinol |
| AM20040816 |
| AKOS015905327 |
| SCHEMBL1262334 |
| 1-(1 phenylcyclohexyl)-4 hydroxypiperidine |
| 1-(1-phenylcyclohexyl) -4-hydroxypiperidine |
| 1-(1 phenylcyclohexyl) 4 hydroxypiperidine |
| piperidine, 1-(1-phenylcyclohexyl)-4-hydroxy |
| 1-(1-phenylcyclohexyl)-4-piperidinol # |
| DTXSID10208979 |
| Q6120311 |
| PD053801 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | K0.5 | 25.0000 | 0.0600 | 0.0600 | 0.0600 | AID150251 |
| Kappa-type opioid receptor | Mus musculus (house mouse) | K0.5 | 25.0000 | 0.0600 | 0.0600 | 0.0600 | AID150251 |
| Mu-type opioid receptor | Mus musculus (house mouse) | K0.5 | 25.0000 | 0.0600 | 0.0600 | 0.0600 | AID150251 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | K0.5 | 2.2000 | 0.0300 | 2.6950 | 8.3000 | AID157449 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Kappa-type opioid receptor | Mus musculus (house mouse) |
| plasma membrane | Mu-type opioid receptor | Mus musculus (house mouse) |
| endoplasmic reticulum membrane | Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) |
| plasma membrane | Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) |
| plasma membrane | Muscarinic acetylcholine receptor M3 | Mus musculus (house mouse) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID141404 | Inhibition of the specific binding of [3H]QNB to Muscarinic acetylcholine receptor | 1982 | Journal of medicinal chemistry, Apr, Volume: 25, Issue:4 | Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. |
| AID24639 | In vitro level of metabolite in mice liver microsomes at 3 hours | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. |
| AID150251 | Inhibition of the specific binding of [3H]morphine to Opioid receptors | 1982 | Journal of medicinal chemistry, Apr, Volume: 25, Issue:4 | Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. |
| AID127656 | Compound was evaluated for the analgesic activity by administering through subcutaneous route in hotplate test; G means not active until 25 mg/Kg Sc | 1981 | Journal of medicinal chemistry, May, Volume: 24, Issue:5 | New analgesic drugs derived from phencyclidine. |
| AID134719 | Lethal dose when administered through subcutaneous route; NT means not tested | 1981 | Journal of medicinal chemistry, May, Volume: 24, Issue:5 | New analgesic drugs derived from phencyclidine. |
| AID24633 | In vitro level of metabolite in mice liver microsomes at 0 hours; ND is Not Detected (< 2 ug/vessel) | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. |
| AID24641 | In vitro level of metabolite in mice liver microsomes at 3 hours (heat inactivated control); ND is Not Detected (< 2 ug/vessel) | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. |
| AID131541 | Effective dose for inhibition of phencyclidine binding measured in mouse rotarod assay | 1982 | Journal of medicinal chemistry, Apr, Volume: 25, Issue:4 | Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. |
| AID24635 | In vitro level of metabolite in mice liver microsomes at 1 hour | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. |
| AID132482 | Compound was evaluated for the inhibition of twitches in mouse vas deferens; J means no change in twitches up to 100 uM | 1981 | Journal of medicinal chemistry, May, Volume: 24, Issue:5 | New analgesic drugs derived from phencyclidine. |
| AID157450 | Hill coefficient for binding of [3H]phencyclidine to phencyclidine receptor | 1982 | Journal of medicinal chemistry, Apr, Volume: 25, Issue:4 | Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. |
| AID127657 | Compound was evaluated for the analgesic activity by administering through subcutaneous route in writhing test | 1981 | Journal of medicinal chemistry, May, Volume: 24, Issue:5 | New analgesic drugs derived from phencyclidine. |
| AID24637 | In vitro level of metabolite in mice liver microsomes at 2 hours | 1985 | Journal of medicinal chemistry, Jan, Volume: 28, Issue:1 | Metabolism of phencyclidine. The role of the carbinolamine intermediate in the formation of lactam and amino acid metabolites of nitrogen heterocycles. |
| AID136963 | Compound was evaluated for the potency to produce hyperactivity in mice | 1981 | Journal of medicinal chemistry, May, Volume: 24, Issue:5 | New analgesic drugs derived from phencyclidine. |
| AID150252 | Hill coefficient for binding of [3H]morphine to Opioid receptors | 1982 | Journal of medicinal chemistry, Apr, Volume: 25, Issue:4 | Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. |
| AID157449 | Inhibition of the specific binding of [3H]phencyclidine to phencyclidine receptor | 1982 | Journal of medicinal chemistry, Apr, Volume: 25, Issue:4 | Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl-piperidine derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.93) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||